Treatment of granulomatous cheilitis with infliximab

Archives of Dermatology

Volumn 141, Issue 9, 2005, Pages 1080-1082

  Barry, Olivia ^a   Barry, Jane ^a   Langan, Sinead ^a   Murphy, Michelle ^a   Fitzgibbon, James ^b   Lyons, James F ^a  

^a SOUTH INFIRMARY VICTORIA UNIVERSITY HOSPITAL   (Ireland)

^b MERCY UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; CORTICOSTEROID; ERYTHROMYCIN STEARATE; INFLIXIMAB; MINOCYCLINE; PREDNISOLONE; TACROLIMUS; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CHEILITIS; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; LIP; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MELKERSSON-ROSENTHAL SYNDROME;

EID: 25444470008     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.141.9.1080     Document Type: Article

References (11)

1. Thomas P, Walchner M, Ghoreschi K, Rocken M. Successful treatment of granulomatous cheilitis with thalidomide. Arch Dermatol. 2003;139:136-138.
2. Kano Y, Shiohara T, Yagita A, Nagashima M. Association between cheilitis granulomatosa and Crohn's disease. J Am Acad Dermatol. 1993;28:801.
3. Baert FJ, D'Haens GR, Peeters M, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology. 1999;116:22-28.
4. Nahar IK, Shojania K, Marra CA, Alamgir AH, Anis AH. Infliximab treatment of rheumatoid arthritis and Crohn's disease. Ann Pharmacother. 2003;37:1256-1265.
5. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology. 2003;124:917-924.
6. Robinson ND, Guitart J. Recalcitrant, recurrent aphthous stomatitis treated with etanercept. Arch Dermatol. 2003;139:1259-1262.
7. Sandborn W, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088-1094.
8. van den Brande JM, Braat H, van den Brink GR. Infliximab but not etanercept induces apoptosis in lamina propria and lymphocytes from patients with Crohn's disease. Gastroenterology. 2003;124:1774-1785.
9. Remicade (infliximab): important safety information. Centocor Inc. Available at: http:/www.remicade.com. Accessed January 21, 2004.
10. Ottaviani F, Schindler A, Capaccio P, Petrone M, Porro GB. New therapy for orolaryngeal manifestations of Crohn's disease. Ann Otol Rhinol Laryngol. 2003;112:37-39.
11. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.